Prostatic Therapeutic Efficacy of Prostanox® : A Novel and Multi-active Principle Formulation

Objective: To demonstrate, with an in vitro approach, the efficacy and safety of a novel, multi-active principle formulation, Prostanox^®, for the prevention and treatment of prostatic diseases, such as benign prostatic hyperplasia and correlated symptoms, with the aim of improving patients well-being.

Methodology: In the present work, we compared, with an in vitro approach based on a prostate and smooth muscle in vitro models, the prostatic safety and efficacy of Prostanox^® with a commercial formulation, based only on Serenoa repens, and a 5αR inhibitor, Finasteride.

Results: Our results showed a better prostatic safety and therapeutic efficacy of Prostanox^®, compared to the commercial formulation and Finasteride, with an increased anti-inflammatory, pro-apoptotic and myorelaxing activity, and a stronger inhibitory effect on the key enzyme 5αR and Prostatic-Specific Antigen (PSA) release.

Conclusion: Based Considering the obtained results, thanks to its unique blend of active principles, Prostanox^® formulation is more promising for BPH and LUTs therapy compared to Serenoa repens only-based formulations.

Author(s): Erik Tedesco1 , Francesca Uberti2 , Vera Morsanuto2 , Luciana Rossi3 and Federico Benetti1

Abstract | Full-Text | PDF

Share This Article